---

• Newark, CA
• NASDAQ: RVNC


• Contact:
  Ron Eastman
  
• Formerly Known As: Essentia BioSystems Inc.
• IPO
• Exit date: February 06, 2014

Related News

• Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration in Largest-Ever Aesthetic Neuromodu
• Revance Announces China Market License Agreement with Fosun Pharma for RT002
• Revance’s RT002 Meets Primary and Secondary Endpoints, Achieves 6-Month Duration in Phase 3 Trials
• Revance Appoints Mark Foley to its Board of Directors
• Revance Announces Positive Results in RT002 Injectable Phase 2 Cervical Dystonia Trial
• Revance Reports Positive Six-Month Duration in BELMONT Study
• Revance Therapeutics Announces Publication of Positive Results from RT002 Phase 1/2 Study
• Revance Therapeutics Added to NASDAQ Biotechnology Index
• Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study Glabellar Frown Lines
• Revance Therapeutics Soars in Debut, While Egalet and Eleven Open Quietly
• Revance Therapeutics Regains All Worldwide Rights to its Botulinum Toxin Products
• Revance Announces $45M Financing